Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

OBJECTIVES: Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response or intol...

Descripción completa

Detalles Bibliográficos
Autores principales: Östör, Andrew, Van den Bosch, Filip, Papp, Kim, Asnal, Cecilia, Blanco, Ricardo, Aelion, Jacob, Alperovich, Gabriela, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Kivitz, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862056/
https://www.ncbi.nlm.nih.gov/pubmed/34815219
http://dx.doi.org/10.1136/annrheumdis-2021-221048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862056/
https://www.ncbi.nlm.nih.gov/pubmed/34815219
http://dx.doi.org/10.1136/annrheumdis-2021-221048

Ejemplares similares